

A1
COO.1

using a variety of techniques, such as immunohistochemistry, in situ hybridization, and the like, in parallel or simultaneously.

Please replace the paragraph at page 47, lines 6 through 19, with the following paragraph:

A2

A sub-category of tumor antigens includes the oncofetal tumor antigens. The oncofetal tumor antigens alphafetoprotein and carcinoembryonic antigen (CEA) are usually only highly expressed in developing embryos, but are frequently highly expressed by tumors of the liver and colon, respectively, in adults. Other oncofetal tumor antigens include, but are not limited to, placental alkaline phosphatase (Deonarain et al., 1997, *Protein Eng.* 10: 89-98; Travers & Bodmer, 1984, *Int. J. Cancer* 33: 633-641), sialyl-Lewis X (adenocarcinoma, Wittig et al., 1996, *Int. J. Cancer* 67: 80-85), CA-125 and CA-19 (gastrointestinal, hepatic, and gynecological tumors; Pitkanen et al., 1994, *Pediatr. Res.* 35: 205-208), TAG-72 (colorectal tumors; Gaudagni et al., 1996, *Anticancer Res.* 16: 2141-2148), epithelial glycoprotein 2 (pan-carcinoma expression; Roovers et al., 1998, *Br. J. Cancer.* 78: 1407-1416), pancreatic oncofetal antigen (Kithier et al., 1992, *Tumor Biol.* 13: 343-351), 5T4 (gastric carcinoma; Starzynska et al., 1998, *Eur. J. Gastroenterol. Hepatol.* 10: 479-484; alphafetoprotein receptor (multiple tumor types, particularly mammary tumors; Moro et al., 1993, *Tumour Biol.* 14: 11-130), and M2A (germ cell neoplasia; Marks et al., 1999, *Brit. J. Cancer* 80: 569-578).

Please delete the paragraph at page 54, line 5.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments".

REMARKS

Claims 1-15 and 35-65 are currently pending in the application. Amendments to the specification have been made to correct typographical errors. No new matter has been added.

Supplemental Information Disclosure Statement

Applicant has filed herewith a Supplemental Information Disclosure Statement.

Restriction Requirement

Regarding the restriction requirement in the present case, the Office Action stated:

During a telephone conversation with Paula Campbell Evans on January 2, 2003 a provisional election was made with traverse to prosecute the invention of Group I, claims 1-15 and 35-65. Affirmation of this election must be made by applicant in responding to